Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation

Guo Zhang, Margaret A. Park, Clint Mitchell, Hossein Hamed, Mohamed Rahmani, Aditi Pandya Martin, David T. Curiel, Adly Yacoub, Martin Graf, Ray Lee, John D. Roberts, Paul B. Fisher, Steven Grant, Paul Dent

Research output: Contribution to journalArticle

81 Scopus citations

Abstract

Purpose and Design: Mechanism(s) by which the multikinase inhibitor sorafenib and the histone deacetylase inhibitor vorinostat interact to kill hepatic, renal, and pancreatic adenocarcinoma cells has been defined. Results: Low doses of sorafenib and vorinostat interacted in vitro in a synergistic fashion to kill hepatic, renal, and pancreatic adenocarcinoma cells in multiple short-term viability (24-96 h) and in long-term colony formation assays. Cell killing was suppressed by inhibition of cathepsin proteases and caspase-8 and, to a lesser extent, by inhibition of caspase-9. Twenty-four hours after exposure, the activities of extracellular signal-regulated kinase 1/2, AKT, and nuclear factor-κB were only modestly modulated by sorafenib and vorinostat treatment. However, 24 h after exposure, sorafenib- and vorinostat-treated cells exhibited markedly diminished expression of c-FLIP-s, full-length BID, BCL-2, BCL-XL, MCL-1, XIAP, increased expression of BIM, and increased activation of BAX, BAK, and BAD. Expression of eIF2α S51A blocked sorafenib- and vorinostat-induced suppression of c-FLIP-s levels and overexpression of c-FLIP-s abolished lethality. Sorafenib and vorinostat treatment increased surface levels of CD95 and CD95 association with caspase-8. Knockdown of CD95 or FADD expression significantly reduced sorafenib/ vorinostat-mediated lethality. Conclusions: These data show that combined exposure of epithelial tumor cell types to sorafenib and vorinostat diminishes expression of multiple antiapoptotic proteins and promotes activation of the CD95 extrinsic apoptotic and the lysosomal protease pathways, and that suppression of c-FLIP-s expression represents a critical event in transduction of the proapoptotic signals from CD95 to promote mitochondrial dysfunction and death.

Original languageEnglish
Pages (from-to)5385-5399
Number of pages15
JournalClinical Cancer Research
Volume14
Issue number17
DOIs
StatePublished - Sep 1 2008
Externally publishedYes

Fingerprint Dive into the research topics of 'Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation'. Together they form a unique fingerprint.

  • Cite this

    Zhang, G., Park, M. A., Mitchell, C., Hamed, H., Rahmani, M., Martin, A. P., Curiel, D. T., Yacoub, A., Graf, M., Lee, R., Roberts, J. D., Fisher, P. B., Grant, S., & Dent, P. (2008). Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clinical Cancer Research, 14(17), 5385-5399. https://doi.org/10.1158/1078-0432.CCR-08-0469